Radiogenomics: bridging imaging and genomics

被引:197
作者
Bodalal, Zuhir [1 ,2 ]
Trebeschi, Stefano [1 ,2 ]
Nguyen-Kim, Thi Dan Linh [1 ,2 ,3 ]
Schats, Winnie [4 ]
Beets-Tan, Regina [1 ,2 ]
机构
[1] Netherlands Canc Inst, Dept Radiol, Amsterdam, Netherlands
[2] Maastricht Univ, Grow Sch Oncol & Dev Biol, Maastricht, Netherlands
[3] Univ Hosp Zurich, Inst Diagnost & Intervent Radiol, Zurich, Switzerland
[4] Netherlands Canc Inst, Sci Informat Serv, Amsterdam, Netherlands
关键词
Radiomics; Quantitative imaging; Radiogenomics; Genomics; Brain neoplasms; Lung neoplasms; Breast neoplasms; Kidney neoplasms; Liver neoplasms; Colorectal neoplasms; Prostate neoplasms; CELL LUNG-CANCER; FACTOR RECEPTOR MUTATION; APPARENT DIFFUSION-COEFFICIENT; QUANTITATIVE TEXTURE ANALYSIS; GENE-EXPRESSION PROGRAMS; PET RADIOMIC FEATURES; LOWER-GRADE GLIOMAS; BREAST-CANCER; MICROVASCULAR INVASION; HEPATOCELLULAR-CARCINOMA;
D O I
10.1007/s00261-019-02028-w
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
From diagnostics to prognosis to response prediction, new applications for radiomics are rapidly being developed. One of the fastest evolving branches involves linking imaging phenotypes to the tumor genetic profile, a field commonly referred to as radiogenomics. In this review, a general outline of radiogenomic literature concerning prominent mutations across different tumor sites will be provided. The field of radiogenomics originates from image processing techniques developed decades ago; however, many technical and clinical challenges still need to be addressed. Nevertheless, increasingly accurate and robust radiogenomic models are being presented and the future appears to be bright.
引用
收藏
页码:1960 / 1984
页数:25
相关论文
共 214 条
[11]  
[Anonymous], J CLIN ONCOLOGY C S1
[12]  
[Anonymous], SCI REP
[13]  
[Anonymous], ONCOSCIENCE
[14]  
[Anonymous], J NEUROLOGICAL SURG
[15]  
[Anonymous], REPRODUCIBILITY NONR
[16]  
[Anonymous], MED IMAGING 2018 COM
[17]  
[Anonymous], ABDOMINAL IMAGING
[18]  
[Anonymous], 2018, J NUCL MED
[19]  
[Anonymous], J CLIN ONCOLOGY C S1
[20]  
[Anonymous], NUKLEARMEDIZIN